The global hyperphosphatemia treatment market grew from $3.57 billion in 2022 to $3.98 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%.

Hyperphosphatemia companies working in the treatment market are Shanghai Alebund Pharmaceuticals, Taisho Pharmaceuticals, Kyowa Kirin Korea Co., Ltd., Keryx Biopharmaceuticals and others, are ...

Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral ...

The aging population is a key driver of market growth, as older adults are more susceptible to CKD, the leading cause of hyperphosphatemia. The prevalence of CKD increases with age, which ...

In this video, Kevin Martin, MD, discusses treatment options available to patients with hyperphosphatemia.

Oxylanthanum carbonate is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients ...

Oxylanthanum carbonate is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients ...

Unicycive’s investigational drug OLC leverages proprietary nanoparticle technology to reduce the number and size of pills that patients must take. If approved, OLC may provide patients and their ...

Based on a survey conducted in 2022, Nephrologists stated that the greatest unmet need in the treatment of hyperphosphatemia with phosphate binders is a lower pill burden and better patient ...

About Hyperphosphatemia Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S.

Major players in the hyperphosphatemia treatment market are Sanofi, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc, Akebia Therapeutics, Inc, Vifor Pharma Management Ltd. , Lupin ...